MIRM - Earnings announcements

- Q1 2026 net product sales of $159.9 million - 2026 net product sales guidance increased to $660 to $680 million - Volixibat VISTAS Phase 2b study met primary endpoint - Brelovitug Phase 2b portion of AZURE-1 study met primary endpoint - In-licensed exclusive worldwide rights to zilurgisertib (ALK2 inhibitor) for FOP; FDA Priority Review granted with September 26, 2026 PDUFA date - Conference call to provide business updates today, May 6 at 1:30 p.m. PT / 4:30 p.m. ET Mirum Pharmaceuticals, Inc. (NASDAQ:MIRM), a leading rare disease company, today reported financial results for the first quarter 2026 and provided a business update. "2026 is off to an excellent start, driven b

- Statistically significant and clinically meaningful 2.72 point reduction from baseline and 1.64 point placebo-adjusted (p=<0.0001) reduction in primary endpoint of cholestatic pruritus - Pre-NDA meeting with the U.S. Food and Drug Administration (FDA) scheduled for summer 2026 - Full results to be presented in late-breaking oral presentation at the EASL International Liver Congress 2026 - Mirum to host conference call to discuss Mirum's recent clinical readouts, today, May 4 at 8:30 am ET Mirum Pharmaceuticals, Inc. (NASDAQ:MIRM), a leading rare disease company, today announced the primary endpoint was met in the VISTAS Phase 2b study evaluating volixibat, an investigational oral

Mirum Pharmaceuticals, Inc. (NASDAQ:MIRM), a leading rare disease company, today announced that it will host an investor call on Monday, May 4, 2026 at 8:30 a.m. ET/5:30 a.m. PT to share topline results from the VISTAS study of volixibat in patients with primary sclerosing cholangitis (PSC). Conference Call Details: US/Toll-Free: + 1 833 461 5787 International: +1 585 542 9983 Access Code: 151345102 You may also access the call via webcast by visiting the Investors section of Mirum's corporate website. The archived webcast will be available for replay. About Mirum Pharmaceuticals Mirum Pharmaceuticals (NASDAQ:MIRM) is a leading rare disease company with a global footprint of appro

Mirum Pharmaceuticals, Inc. (NASDAQ:MIRM), a leading rare disease company, today announced that it will report first quarter 2026 financial results on May 6, 2026. Mirum will also host a conference call to discuss the first quarter 2026 financial results and recent corporate progress. Conference call details: Wednesday, May 6, 2026 4:30 p.m. ET / 1:30 p.m. PT Dial-In: US/Toll-Free: + 1 833 461 5787 International: +1 585 542 9983 Access Code: 487977865 You may also access the call via webcast by visiting the Investors section of Mirum's corporate website. The archived webcast will be available for replay. About Mirum Pharmaceuticals Mirum Pharmaceuticals (NASDAQ:MIRM) is a leading

- 2025 net product sales of $521 million - 2026 expected global net product sales of $630 million to $650 million - Volixibat VISTAS study in PSC topline data expected Q2 2026 - LIVMARLI® EXPAND study in additional cholestatic pruritus settings topline data expected Q4 2026 - Brelovitug AZURE-1 and AZURE-4 studies in HDV topline data expected H2 2026 - Conference call to provide business updates today, February 25 at 1:30 p.m. PT/4:30 p.m. ET Mirum Pharmaceuticals, Inc. (NASDAQ:MIRM), a leading rare disease company, today reported financial results for the fourth quarter and year-end 2025 and provided a business update. "2025 was a year of meaningful progress and execution for

Mirum Pharmaceuticals, Inc. (NASDAQ:MIRM) today announced that it will report fourth quarter and year-end 2025 financial results on February 25, 2026. Mirum will also host a conference call to discuss the fourth quarter and year-end 2025 financial results and recent corporate progress. Conference call details: Wednesday, February 25, 2026 4:30 p.m. ET / 1:30 p.m. PT Dial-In: US/Toll-Free: +1 833 470 1428 International: +1 646 844 6383 Access Code: 047642 You may also access the call via webcast by visiting the Investors section of Mirum's corporate website. The archived webcast will be available for replay. About Mirum Pharmaceuticals, Inc. Mirum Pharmaceuticals (NASDAQ:MIRM) is a

-Planned acquisition of brelovitug for chronic hepatitis delta virus (HDV) with Breakthrough Therapy and PRIME designations -Anticipated to be highly synergistic with Mirum's liver expertise and proven global commercial capabilities -HDV: Large, high unmet-need rare liver disease with no FDA-approved therapies -Top-line Phase 3 results expected in 2H 2026 -Conference call today, December 8, 2025 at 8:30 am ET/5:30 am PT Mirum Pharmaceuticals, Inc. (NASDAQ:MIRM), a leading rare disease company, today announced its entry into a definitive agreement to acquire Bluejay Therapeutics, a privately held biotechnology company focused on viral and liver diseases. The transaction would add worldw

- Third quarter 2025 total revenue of $133 million - 2025 revenue guidance updated to $500 to $510 million - Phase 2b VISTAS topline data expected second quarter of 2026 - Conference call to provide business updates today, November 4 at 1:30 p.m. PT / 4:30 p.m. ET Mirum Pharmaceuticals, Inc. (NASDAQ:MIRM) today reported financial results for the third quarter 2025 and provided a business update. "Mirum is well positioned heading into 2026 with strong commercial momentum and multiple upcoming catalysts," said Chris Peetz, Chief Executive Officer of Mirum. "Our third quarter results once again underscore the strength of our commercial medicines with continued strong performance. We also

Mirum Pharmaceuticals, Inc. (NASDAQ:MIRM) today announced that it will report third quarter 2025 financial results on November 4, 2025. Mirum will also host a conference call to discuss the third quarter 2025 financial results and recent corporate progress. Conference call details: Tuesday November 4th, 2025 4:30 p.m. ET / 1:30 p.m. PT Dial-In: US/Toll-Free: +1 833 470 1428 International: +1 646 844 6383 Access Code: 299722 You may also access the call via webcast by visiting the Events & Presentations section on Mirum's website. A replay of this webcast will be available for 30 days. About Mirum Pharmaceuticals, Inc. Mirum Pharmaceuticals, Inc. is a biopharmaceutical company dedica

- Second quarter 2025 total revenue of $128 million - 2025 revenue guidance increased to $490 to $510 million - Conference call to provide business updates today, August 6 at 1:30 p.m. PT / 4:30 p.m. ET Mirum Pharmaceuticals, Inc. (NASDAQ:MIRM) today reported financial results for the second quarter 2025 and provided a business update. "Our second quarter results once again underscore the strength of our commercial programs with notable outperformance from our International business and U.S. PFIC launch," said Chris Peetz, chief executive officer of Mirum. "The momentum we are seeing with Livmarli globally reinforces our belief that the medicine will reach and help more patients tha

Mirum Pharmaceuticals, Inc. (NASDAQ:MIRM) today announced that it will report second quarter 2025 financial results on August 6, 2025. Mirum will also host a conference call to discuss the second quarter 2025 financial results and recent corporate progress. Conference call details: Wednesday, August 6th, 2025 4:30 p.m. ET / 1:30 p.m. PT Dial-In: U.S./Toll-Free: +1 833 470 1428 International: +1 404 975 4839 Access Code: 448461 You may also access the call via webcast by visiting the Events & Presentations section on Mirum's website. A replay of this webcast will be available for 30 days. About Mirum Pharmaceuticals, Inc. Mirum Pharmaceuticals, Inc. is a biopharmaceutical

- First quarter 2025 total revenue of $111.6 million; 2025 guidance increased to $435 to $450 million - VISTAS study in PSC expected to complete enrollment in third quarter of 2025; topline data expected in second quarter of 2026 - LIVMARLI oral tablet formulation FDA approved - Conference call to provide business updates today, May 7 at 1:30 p.m. PT/4:30 p.m. ET Mirum Pharmaceuticals, Inc. (NASDAQ:MIRM) today reported financial results for the first quarter 2025 and provided a business update. "It's been a strong start to the year with commercial growth and multiple milestones achieved across our pipeline," said Chris Peetz, chief executive officer of Mirum. "We're pleased with the FD

Mirum Pharmaceuticals, Inc. (NASDAQ:MIRM) today announced that it will report first quarter 2025 financial results on Wednesday, May 7, 2025. Mirum will also host a conference call to discuss the first quarter 2025 financial results and recent corporate progress. Conference call details: Wednesday, May 7, 2025 4:30 p.m. ET / 1:30 p.m. PT Dial-in: U.S./Toll-Free: + 1 833 470 1428 International: + 1 404 975 4839 Passcode: 549600 You may also access the call via webcast by visiting the Events & Presentations section on Mirum's website. A replay of this webcast will be available for 30 days. About Mirum Pharmaceuticals, Inc. Mirum Pharmaceuticals, Inc. is a biopharmaceutical company d

- 2024 net product sales of $336.4 million - 2025 expected global net product sales of $420 million to $435 million - VISTAS study of volixibat in PSC expected to complete enrollment in second half 2025; topline data expected 2026 - CTEXLI (chenodiol) approved in the US for cerebrotendinous xanthomatosis - Conference call to provide business updates today, February 26 at 1:30 p.m. PT/4:30 p.m. ET Mirum Pharmaceuticals, Inc. (NASDAQ:MIRM) today reported financial results for the fourth quarter and year-end 2024 and provided a business update. "2024 was another year of significant growth and accomplishments for Mirum and in 2025 we expect this momentum to continue," said Chris Pee

Mirum Pharmaceuticals, Inc. (NASDAQ:MIRM) today announced that it will report fourth quarter and year-end 2024 financial results on Wednesday, February 26, 2025. Mirum will also host a conference call to discuss the fourth quarter and year-end 2024 financial results and recent corporate progress. Conference call details: Wednesday, February 26, 2025 4:30 p.m. ET / 1:30 p.m. PT Dial-in: U.S./Toll-Free: + 1 833 470 1428 International: + 1 404 975 4839 Passcode: 126145 You may also access the call via webcast by visiting the Events & Presentations section on Mirum's website. A replay of this webcast will be available for 30 days. About Mirum Pharmaceuticals Mirum Pharmaceuticals, Inc

Third quarter global net product sales of $90.3 million; 2024 guidance increased to $330 - 335 million Volixibat granted breakthrough therapy designation for treatment of cholestatic pruritus in PBC, interim results to be presented as a Late Breaker presentation at AASLD's The Liver Meeting® 2024 PDUFA date for chenodiol in CTX is December 28, 2024 In-licensed global rights to PDE4D inhibitor MRM-3379 Conference call to provide business updates today, November 12 at 5:30 a.m. PT/8:30 a.m. ET Mirum Pharmaceuticals, Inc. (NASDAQ:MIRM) today reported financial results for the third quarter 2024 and provided a business update. "The Mirum team executed across all aspects of the

Mirum Pharmaceuticals, Inc. (NASDAQ:MIRM) today announced that it will report third quarter 2024 financial results on November 12, 2024. Mirum will also host a conference call to discuss the third quarter 2024 financial results and recent corporate progress. Conference call details: Tuesday, November 12, 2024 8:30 a.m. ET / 5:30 a.m. PT Dial-in: U.S./Toll-Free: + 1 833 470 1428 International: + 1 404 975 4839 Passcode: 749358 You may also access the call via webcast by visiting the Events & Presentations section on Mirum's website. A replay of this webcast will be available for 30 days. About Mirum Pharmaceuticals, Inc. Mirum Pharmaceuticals, Inc. is a biopharmaceutical company

Second quarter global net product sales of $77.8 million, on track to achieve full-year guidance of $310 to $320 million Positive interim results for volixibat in VISTAS PSC and VANTAGE PBC studies LIVMARLI for treatment of PFIC granted marketing authorization in Europe Initiating LIVMARLI EXPAND study for pruritus in rare cholestatic conditions Conference call to provide business updates today, August 7 at 1:30 p.m. PT/4:30 p.m. ET Mirum Pharmaceuticals, Inc. (NASDAQ:MIRM) today reported financial results for second quarter 2024 and provided a business update. "The second quarter was marked by significant achievements across both our commercial medicines and development p

Mirum Pharmaceuticals, Inc. (NASDAQ:MIRM) today announced that it will report second quarter 2024 financial results on August 7, 2024. Mirum will also host a conference call to discuss the second quarter 2024 financial results and recent corporate progress. Conference call details: Wednesday, August 7, 2024 4:30 p.m. ET / 1:30 p.m. PT Dial-in: U.S./Toll-Free: +1 833 470 1428 International: +1 404 975 4839 Passcode: 771307 You may also access the call via webcast by visiting the Events & Presentations section on Mirum's website. A replay of this webcast will be available for 30 days. About Mirum Pharmaceuticals, Inc. Mirum Pharmaceuticals, Inc. is a biopharmaceutical company dedica

- VANTAGE PBC interim analysis shows 3.8 point reduction from baseline and 2.3 point placebo-adjusted (p=0.0026) reduction in primary endpoint of pruritus - VISTAS PSC interim analysis exceeds efficacy threshold for study continuation - Mirum to host conference call to discuss analyses, today, June 17 at 8:30 a.m. ET/5:30 a.m. PT Mirum Pharmaceuticals, Inc. (NASDAQ:MIRM) today announced interim results from two Phase 2b studies evaluating volixibat, an oral ileal bile acid transporter (IBAT) inhibitor in patients with primary biliary cholangitis (PBC) and primary sclerosing cholangitis (PSC). Interim results from the VANTAGE study evaluating volixibat in patients with PBC demonstrat

Mirum Pharmaceuticals, Inc. (NASDAQ:MIRM) today announced that it will host an investor call on Monday, June 17 at 8:30 a.m. ET to share interim analysis results from the Volixibat VANTAGE Phase 2b study in primary biliary cholangitis (PBC) and the Volixibat VISTAS Phase 2b study in primary sclerosing cholangitis (PSC). Conference call details: Monday June 17, 2024 8:30 a.m. ET / 5:30 a.m. PT Dial-in: U.S./Toll-Free: +1 833 470 1428 International: +1 404 975 4839 Passcode: 205511 You may also access the call via webcast by visiting the Events & Presentations section on Mirum's website. A replay of this webcast will be available for 30 days. About Mirum Pharmaceuticals, In

- First quarter 2024 total revenue of $69.2 million, on track to achieve full-year guidance of $310 to $320 million - FDA approval of LIVMARLI for cholestatic pruritus in PFIC patients achieved in March - Volixibat VISTAS and VANTAGE interim analyses scheduled for June of 2024 - Cash balance of $302.8 million as of March 31, 2024 - Conference call to provide business updates today, May 8 at 1:30 p.m. PT/4:30 p.m. ET Mirum Pharmaceuticals, Inc. (NASDAQ:MIRM) today reported financial results for first quarter 2024 and provided a business update. "In the first quarter, we made great progress across a number of our strategic objectives that support both the near- and long-term growth of Mir

Mirum Pharmaceuticals, Inc. (NASDAQ:MIRM) today announced that it will report first quarter 2024 financial results on May 8, 2024. Mirum will also host a conference call to discuss the first quarter 2024 financial results and recent corporate progress. Conference call details: Wednesday, May 8, 2024 4:30 p.m. ET / 1:30 p.m. PT Dial-in: U.S./Toll-Free: +1 833 470 1428 International: +1 404 975 4839 Passcode: 479107 You may also access the call via webcast by visiting the Events & Presentations section on Mirum's website. A replay of this webcast will be available for 30 days. About Mirum Pharmaceuticals, Inc. Mirum Pharmaceuticals, Inc. is a biopharmaceutical company dedicated to t

- Net product sales totaled $178.9 million, and full year 2023 revenue totaled $186.4 million, delivering 142% growth over 2022 total revenue - 2024 expected global net product sales of $310 million to $320 million - LIVMARLI PFIC PDUFA date on track for March 13, 2024 - Volixibat VISTAS and VANTAGE interim analyses expected in first half of 2024 - Conference call to provide business updates today, February 28 at 1:30 p.m. PT/4:30 p.m. ET Mirum Pharmaceuticals, Inc. (NASDAQ:MIRM) today reported financial results for the fourth quarter and year-end 2023 and provided a business update. "2023 was a landmark year for Mirum as we significantly expanded our commercial footprint, reali

Mirum Pharmaceuticals, Inc. (NASDAQ:MIRM) today announced that it will report fourth quarter and year-end 2023 financial results on Wednesday, February 28, 2024. Mirum will also host a conference call to discuss the fourth quarter and year-end 2023 financial results and recent corporate progress. Conference call details: Wednesday, February 28, 2024 4:30 p.m. ET / 1:30 p.m. PT Dial-in: U.S./Toll-Free: +1 833 470 1428 International: +1 404 975 4839 Passcode: 089049 You may also access the call via webcast by visiting the Events & Presentations section on Mirum's website. A replay of this webcast will be available for 30 days. About Mirum Pharmaceuticals, Inc. Mirum Pharmaceuticals,

- Third quarter 2023 total revenue of $47.7 million - Completed acquisition of CHENODAL® and CHOLBAM® - Announced positive Phase 3 RESTORE study results evaluating CHENODAL (chenodiol) in patients with CTX; NDA filing expected in H1 2024 - Conference call to provide business updates today, November 2 at 1:30 p.m. PT/4:30 p.m. ET Mirum Pharmaceuticals, Inc. (NASDAQ:MIRM) today reported financial results for third quarter 2023 and provided a business update. "We made significant progress in the third quarter with record LIVMARLI revenues in both the United States and Internationally, the closing of the acquisition of CHENODAL and CHOLBAM and the positive top line results from the unblindi

Mirum Pharmaceuticals, Inc. (NASDAQ:MIRM) today announced that it will report third quarter 2023 financial results on Thursday, November 2nd, 2023. Mirum will also host a conference call to discuss the third quarter 2023 financial results and recent corporate progress. Conference call details: Thursday, November 2nd, 2023 4:30 p.m. ET / 1:30 p.m. PT Dial-in: U.S./Toll-Free: +1 833 470 1428 International: +1 404 975 4839 Passcode: 979561 You may also access the call via webcast by visiting the Events & Presentations section on Mirum's website. A replay of this webcast will be available for 30 days. About Mirum Pharmaceuticals, Inc. Mirum Pharmaceuticals, Inc. is a biopharmaceutical

- $37.5 million total revenue, including net product sales for LIVMARLI® (maralixibat) oral solution of $32.5 million, for second quarter 2023 - Acquiring CHENODAL® and CHOLBAM®, advancing Mirum's leadership in pediatric hepatology with a multi-product franchise - Four late-stage clinical trial data readouts expected later this year - Conference call to provide business updates today, August 3 at 1:30 p.m. PT/4:30 p.m. ET Mirum Pharmaceuticals, Inc. (NASDAQ:MIRM) today reported financial results for second quarter 2023 and provided a business update. "Our goal is to continue to bring life-changing medicines to patients with rare disease. Use of LIVMARLI in Alagille Syndrome continues to

Mirum Pharmaceuticals, Inc. (NASDAQ:MIRM) today announced that it will report second quarter 2023 financial results on Thursday, August 3, 2023. Mirum will also host a conference call to discuss the second quarter 2023 financial results and recent corporate progress. Conference call details: Thursday, August 3, 2023 4:30 p.m. ET / 1:30 p.m. PT Dial-in: U.S./Toll-Free: +1 833 470 1428 International: + 1 404 975 4839 Passcode: 969043 You may also access the call via webcast by visiting the Events & Presentations section on Mirum's website. A replay of this webcast will be available for 30 days. About Mirum Pharmaceuticals, Inc. LIVMARLI® (maralixibat) oral solution is an orally admi

Mirum to acquire all of Travere's rights and assets related to Cholbam® and Chenodal® Travere to receive up to $445 million with $210 million upfront and up to $235 million in potential sales-based milestones Mirum announces concurrent private placement of $210 million, funding upfront payment Expands Mirum's leadership in rare liver disease with two commercial products and a near-term Phase 3 label expansion opportunity Advances Travere's strategy to deliver new treatment standards from its pipeline of innovative medicines for rare diseases and strengthens financial foundation Mirum to host conference call today, July 17, 2023, at 8:30 a.m. ET/5:30 a.m. PT Mirum Pharmace

- $31.6 million total revenue, including net product sales for LIVMARLI® (maralixibat) oral solution of $29.1 million, for first quarter 2023 - Conference call to provide business updates today, May 4 at 1:30 p.m. PT/4:30 p.m. ET Mirum Pharmaceuticals, Inc. (NASDAQ:MIRM) today reported financial results for first quarter 2023 and provided a business update. "We began 2023 with significant momentum, achieving $29.1 million in net product sales for LIVMARLI," said Chris Peetz, president and chief executive officer at Mirum. "In addition to the progress of our global LIVMARLI commercial launch, our recent U.S. label expansion for LIVMARLI in Alagille syndrome to include infants three month

Mirum Pharmaceuticals, Inc. (NASDAQ:MIRM) today announced that it will report first quarter 2023 financial results on Thursday, May 4, 2023. Mirum will also host a conference call to discuss the first quarter 2023 financial results and recent corporate progress. Conference call details: Thursday, May 4, 2023 4:30 p.m. ET / 1:30 p.m. PT Dial-in: U.S./Toll-Free: 1 833 470 1428 International: 1 404 975 4839 Passcode: 557272 You may also access the call via webcast by visiting the Events & Presentations section on Mirum's website. A replay of this webcast will be available for 30 days. About Mirum Pharmaceuticals, Inc. Mirum Pharmaceuticals, Inc. is a biopharmaceutical company dedicat

- Net product sales for LIVMARLI® (maralixibat) oral solution totaled $75.1 million for first full fiscal year of U.S. commercial launch, and full year 2022 revenue totaled $77.1 million - Conference call to provide business updates today, March 8 at 1:30 p.m. PT/4:30 p.m. ET Mirum Pharmaceuticals, Inc. (NASDAQ:MIRM) today reported financial results for the fourth quarter and year-end 2022 and provided a business update. "We are proud of our strong commercial, clinical and regulatory execution in 2022 that realized $75.1 million in LIVMARLI net product sales in the first full fiscal year of our U.S. launch and groundbreaking clinical data for our Alagille syndrome and progressive familia

Mirum Pharmaceuticals, Inc. (NASDAQ:MIRM) today announced that it will report fourth quarter and year-end 2022 financial results on Wednesday, March 8, 2023. Mirum will also host a conference call to discuss the fourth quarter and year-end 2022 financial results and recent corporate progress. Conference call details: Wednesday, March 8, 2023 4:30 p.m. ET / 1:30 p.m. PT Dial-in: U.S./Toll-Free: 1 833 927 1758 International: 1 929 526 1599 Passcode: 596100 You may also access the call via webcast by visiting the Events & Presentations section on Mirum's website. A replay of this webcast will be available for 30 days. About Mirum Pharmaceuticals, Inc. Mirum Pharmaceuticals, Inc. is a biop

-          Phase 3 MARCH study meets primary endpoint and demonstrates statistical significance across key endpoints in all PFIC types. Receives Best of Liver Meeting distinction. -          RISE study in infants with ALGS shows safety and tolerability of LIVMARLI for ages ≥2 months. -          Real-world evidence highlights LIVMARLI's safety and tolerability in patients with ALGS. -          Post-AASLD conference call to discuss MARCH data on November 9, 2022 at 8am ET/5am PT Mirum Pharmaceuticals, Inc. (NASDAQ:MIRM), today presented new data from LIVMARLI® (maralixibat) oral solution studies, including two late-breaker presentations, at The Liver Meeting® of the American Association for

Mirum Pharmaceuticals, Inc. (NASDAQ:MIRM) today announced that it will report third quarter financial results on Wednesday, November 9, 2022. Mirum will host a conference call to discuss the third quarter financial results and recent corporate progress. Mirum will be joined by guest speaker Richard J. Thompson, M.D., professor of molecular hepatology Kings College, London to discuss LIVMARLI and the results from the MARCH Phase 3 study. Conference call details: Wednesday, November 9, 2022 8:00 a.m. ET / 5:00 a.m. PT Dial-in: U.S./Toll-Free: 1 844 200 6205 International: 1 929 526 1599 Passcode: 582604 You may also access the call via webcast by visiting the Events & Presentations sectio

Met primary endpoint (p=0.0098); highly statistically significant effects in all PFIC subtypes. Significant improvements in total bilirubin and growth versus placebo at six months. Mirum plans to submit these data to regulatory agencies. Mirum to host conference call to discuss data today, October 24, at 9:00 a.m. ET/6:00 a.m. PT. Mirum Pharmaceuticals, Inc. (NASDAQ:MIRM) today announced positive topline results from its pivotal Phase 3 MARCH study evaluating LIVMARLI® (maralixibat) oral solution in 93 patients with progressive familial intrahepatic cholestasis (PFIC) in a broad range of subtypes, age one to 17 years. The primary endpoint of improvement in pruritus severity in PFIC

- Net product sales for LIVMARLI® (maralixibat) oral solution totaled $17.5 million in the second quarter of 2022 and $28.4 million year-to-date - Conference call to provide business updates today, August 4 at 1:30 p.m. PT/4:30 p.m. ET Mirum Pharmaceuticals, Inc. (NASDAQ:MIRM) today reported financial results for the second quarter ended June 30, 2022 and provided a business update. "It is inspiring to see LIVMARLI's impact on the burden of disease in Alagille syndrome and we continue to see growing demand with $17.5 million in net product sales in the second quarter," said Chris Peetz, president and chief executive officer of Mirum. "We expect a strong finish to 2022 with topline MARCH

Mirum Pharmaceuticals, Inc. (NASDAQ:MIRM) today announced that it will report second quarter financial results on Thursday, August 4, 2022. That same day, Mirum will host a conference call to discuss the company's progress and priorities for 2022. Conference call details: Thursday, August 4, 2022 4:30 p.m. ET / 1:30 p.m. PT Dial-in: U.S./Toll-Free: 1 (888) 510-2553 International: 1 (646) 960-0473 Passcode: 9354200 You may also access the call via webcast by visiting the Events & Presentations section on Mirum's website. A replay of this webcast will be available for 30 days. About Mirum Pharmaceuticals, Inc. Mirum Pharmaceuticals, Inc. is a biopharmaceutical company dedicated to transf

- Total revenue for the first quarter of 2022 was $12.9 million including net product revenue for LIVMARLI® (maralixibat) oral solution of $10.9 million. - Conference call to provide business updates today, May 5 at 5:30 a.m. PT/8:30 a.m. ET Mirum Pharmaceuticals, Inc. (NASDAQ:MIRM) today reported financial results for the first quarter ended March 31, 2022 and provided a business update. "The first quarter was tremendously successful for Mirum. Rapid growth in LIVMARLI revenue means that children suffering from pruritus associated with Alagille syndrome finally have a treatment option and are getting the care they need," said Chris Peetz, president and chief executive officer. "I am thr

Mirum Pharmaceuticals, Inc. (NASDAQ:MIRM) today announced that it will report first quarter financial results on Thursday, May 5, 2022. That same day, Mirum will host a conference call to discuss the company's progress and priorities for 2022. Conference call details: Thursday, May 5, 2022 8:30 a.m. ET/5:30 a.m. PT Dial-in: U.S./Toll-Free: 844-200-6205 International: 646-904-5544 Passcode: 717854 You may also access the call via webcast by visiting the Events & Presentations section on Mirum's website. A replay of this webcast will be available for 30 days. About Mirum Pharmaceuticals, Inc. Mirum Pharmaceuticals, Inc. is a biopharmaceutical company dedicated to transforming the treatme

- Strong commercial launch underway with LIVMARLI® (maralixibat) oral solution; net product revenue of $3.1 million for the first quarter of launch, total 2021 company revenue of $19.1 million - Expect at least $8.0 million in LIVMARLI net product sales in first quarter 2022 - Conference call to provide business updates today, March 9 at 1:30 p.m. PT/4:30 p.m. ET Mirum Pharmaceuticals, Inc. (NASDAQ:MIRM) today reported financial results for the fourth quarter and year-end 2021 and provided a business update. "2021 marked a significant turning point for Mirum and the Alagille syndrome community. With a strong start to our launch of LIVMARLI, the first and only FDA-approved medication for

Mirum Pharmaceuticals, Inc. (NASDAQ:MIRM) today announced that it will report fourth quarter and year-end 2021 results on Wednesday, March 9, 2022. That same day, Mirum will host a conference call to discuss the company's progress and achievements in 2021 as well as priorities for 2022. Conference call details: Wednesday, March 9, 2022 4:30 p.m. ET / 1:30 p.m. PT Dial-in: U.S./Toll-Free: 833-927-1758 International: 646-904-5544 Passcode: 521837 You may also access the call via webcast by visiting the Events & Presentations section on Mirum's website. A replay of this webcast will be available for 30 days. About Mirum Pharmaceuticals, Inc. Mirum Pharmaceuticals, Inc. is a biopharmaceuti

- U.S. commercial launch underway following U.S. FDA approval of LIVMARLI™ (maralixibat) oral solution - Six-year analysis showing significant improvement in event-free survival with LIVMARLI compared to natural history cohort (p<0.0001) presented as late-breaking, Best of The Liver Meeting presentation at the American Association for the Study of Liver Diseases (AASLD) The Liver Meeting® 2021 - The Lancet published data from the pivotal LIVMARLI ICONIC study demonstrating significant and durable responses in pruritus and other clinically meaningful improvements in patients with ALGS - Conference call to provide business updates and discuss data presented at AASLD today, November 15 at 1

Mirum Pharmaceuticals, Inc. (NASDAQ:MIRM) today announced that the company will report financial results for the quarter ended September 30, 2021 on Monday, November 15, 2021. That same day, Mirum will host a conference call and audio webcast at 1:30 p.m. PT/4:30 p.m. ET to provide a business update. Conference Call Details: U.S. toll-free: 844.200.6205 International: 646.904.5544 Passcode: 588077 You may also access the call via webcast by visiting the Investors & Media section on Mirum's corporate website. A replay of this webcast will be available for 30 days. About Mirum Pharmaceuticals, Inc. Mirum Pharmaceuticals, Inc. is a biopharmaceutical company dedicated to transforming the t

Mirum to host an investor call on September 29, 2021 at 4:30 p.m. ET Mirum Pharmaceuticals, Inc. (NASDAQ:MIRM), a leader in rare liver disease, today announced that the U.S. Food and Drug Administration (FDA) has approved LIVMARLI™ (maralixibat) oral solution for the treatment of cholestatic pruritus in patients with Alagille syndrome (ALGS) one year of age and older. LIVMARLI, a minimally absorbed ileal bile acid transporter (IBAT) inhibitor, is the first and only FDA-approved medication in this rare liver disease which affects 2,000 to 2,500 children in the United States. LIVMARLI is now available for prescribing. In conjunction with the approval, Mirum received a rare pediatric disease

- NDA for maralixibat for cholestatic pruritus in Alagille syndrome under priority review; PDUFA date is September 29, 2021 - Commercial preparations complete in anticipation of U.S. launch of maralixibat in ALGS - Conference call to provide business update today, August 5 at 1:30 p.m. PT/4:30 p.m. ET Mirum Pharmaceuticals, Inc. (NASDAQ:MIRM), today reported financial results for the quarter ended June 30, 2021 and provided a business update. "We are pleased with the progress we have made in the last quarter as we prepare for the potential FDA approval of maralixibat and advance our late-stage clinical development pipeline," said Chris Peetz, president and chief executive officer at Mirum

Mirum Pharmaceuticals, Inc. (NASDAQ:MIRM), today announced that the company will report financial results for the quarter ended June 30, 2021 on Thursday, August 5, 2021. That same day, Mirum will host a conference call and audio webcast at 1:30 p.m. PT/4:30 p.m. ET to provide a business update. Conference Call Details: U.S. toll-free: 844.200.6205 International: 646.904.5544 Passcode: 097025 You may also access the call via webcast by visiting the Investors & Media section on Mirum's corporate website. A replay of this webcast will be available for 30 days. About Mirum Pharmaceuticals Mirum Pharmaceuticals, Inc. is a clinical-stage biopharmaceutical company